DealsJul 28, 2026, 07:08 AM
Lifecore Secures 3 New Customer Agreements, Expands Pipeline
AI Summary
Lifecore Biomedical, Inc. announced it has signed three new customer agreements, significantly expanding its pipeline of early- and late-stage programs. These agreements include a late-stage development program in regenerative medicine and two early-stage programs, one with a global medical technology company. The company expects these new programs to generate near-term development revenue and contribute to its 2028 revenue, positioning Lifecore for future growth in high-growth markets.
Key Highlights
- Lifecore Biomedical signed three new customer agreements.
- One agreement is for a late-stage regenerative medicine development program.
- Two agreements are for early-stage programs, including one with a global medical technology company.
- The late-stage program involves technology transfer, GMP readiness, and process performance qualification.
- The early-stage programs include formulation optimization and development support.
- All programs are expected to contribute to Lifecore's 2028 revenue.
- The late-stage program is expected to generate near-term development revenue.
Price Impact
More from LFCR